Stocks · News reference

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Aug 6, 2026, 5:56 PMVandana Singh

Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARSep 4, 2026, 8:45 PMSEC EDGAR
8-K filing — HARROW, INC. (HROW)
Filed: 2026-09-04 AccNo: 0001493152-26-041569 Size: 207 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
HROW
BenzingaAug 21, 2026, 4:09 PMVandana Singh
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
HROW
BenzingaAug 20, 2026, 11:04 AMBenzinga Newsdesk
Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
HROW
BenzingaAug 11, 2026, 6:03 PMBenzinga Newsdesk
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
HROW
BenzingaAug 6, 2026, 6:55 PMBenzinga Newsdesk
Viatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.
VTRS
SEC EDGARAug 6, 2026, 11:56 AMSEC EDGAR
8-K filing — Viatris Inc (VTRS)
Filed: 2026-08-06 AccNo: 0001792044-26-000037 Size: 874 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
VTRS